Pediatric fungal infections are associated with significant morbidity and mortality. Few adequately powered antifungal trials have been performed in neonates and children. Neonatologists and pediatricians are reliant on adult trials when managing candidemia. Recent guidelines from the Infectious Diseases Society of America recommend fluconazole or an echinocandin for empiric therapy in suitable candidates, with a preference for an echinocandin in patients with moderate-to severe disease, recent azole exposure, or high risk of C. glabrata or C. krusei infection
Finco, G., Sanna, D., Evangelista, M., Mura, P., Musu, M., Fungal infections in pediatric intensive care units, <<THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE>>, 2011; 24 (2s): 22-24. [doi:10.3109/14767058.2011.601922] [http://hdl.handle.net/10807/64385]
Fungal infections in pediatric intensive care units
Evangelista, Maurizio;
2011
Abstract
Pediatric fungal infections are associated with significant morbidity and mortality. Few adequately powered antifungal trials have been performed in neonates and children. Neonatologists and pediatricians are reliant on adult trials when managing candidemia. Recent guidelines from the Infectious Diseases Society of America recommend fluconazole or an echinocandin for empiric therapy in suitable candidates, with a preference for an echinocandin in patients with moderate-to severe disease, recent azole exposure, or high risk of C. glabrata or C. krusei infection
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
